

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Managers:

Stephanie Osorio
Judit Castellanos

Clinical Research Coordinators:

Alice Ting
Kelsey Edwards
Georgina Alvarez-Diaz
Melisa Duvnjak
Makena Castillo
Cristian Franco
Jeffrey Caluag
Phoebe Lee

Data Coordinators:

Heather Franson
Mario Diaz
Sarahy Martinez

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 26-12 (NEW)

A Phase 3 Randomized,
Double-blind, Placebo-
controlled Global Study of
Sapablursen in Polycythemia
Vera
Accrual: 0
CRC: TBD

UCI 20-50

N-Acetylcysteine in MPN to
Improve Disease Markers &
Symptoms
Accrual 15/27
CRC: Kelsey E.

ETCTN 10675

A Randomized Phase II Trial
of ASTX727 +/-
Iadademstat in
Accelerated/Blast-Phase
Philadelphia Chromosome-
Negative
Myeloproliferative
Neoplasms (MPNs)
Accrual: 0/5
CRC: Georgina A.

Newly diagnosed

High-Risk

MM1MDS-A01

A Randomized Phase II Trial
of Enasidenib-Based
Therapies Versus
Cedazuridine-Decitabine in
Higher-Risk IDH2-Mutated
Myelodysplastic Syndrome: A
MyeloMATCH Sub-Study

Accrual: 0/5

CRC: Georgina Alvarez

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Low-Risk

Molecularly-Driven

HSCT

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Low-Risk

UCI 21-239

IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual: 2/5

CRC: Georgina A.

UCI 25-193

ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 1/10

CRC: Georgina A.

Molecularly-Driven

High-Risk

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Intensive

ETCTN-10596

SNDX-5613 + Daunorubicin
and Cytarabine in Newly
Diagnosed Acute Myeloid
Leukemia (NPM1
Mutated/FLT3 Wildtype with
Higher-Risk Features or
MLL/KMT2A Rearranged)

Accrual: 0/5

CRC: Georgina Alvarez

MYELOMATCH

MYELOMATCH, Master
Screening and Reassessment
Protocol (MSRP) for Tier
Advancement in the NCI
MyeloMATCH Clinical Trials

Accrual: 0/5

CRC: Makena Belle Castillo

UCI 23-44

Venetoclax/Azacitidine v.s
Venetoclax+ KO-530 v.s
cytarabine/daunorubicin
(7+3)+ KO-539 in AML

Accrual: 10/10

CRC: Georgina A.

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Non-Intensive

ETCTN-10630 (Suspended)

Ladademstat in Combination
with Venetoclax and
Azacitidine in Patients with
Post MDS Transformation to
AML

Accrual: 2/7

CRC: Georgina Alvarez

UCI 22-81

HM43239 in patients w/ R/R
AML

Accrual: 4/6

CRC: Georgina A.

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Non-Intensive

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s
 Venetoclax+ KO-530 v.s
 cytarabine/daunorubicin (7+3)+
 KO-539 in AML

Accrual: 10/10

CRC: Georgina A.

FLT3 mutation

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Non-Intensive

KMT2A-r/NPM1-m

UCI 25-20

Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged AML

Accrual: 4/5

CRC: Georgina A.

IDH1-R132-m

UCI 25-90

Olutasidenib in Combination with Azacitidine Followed by Olutasidenib Maintenance After Venetoclax Plus a Hypomethylating Agent Regimen (HMA-VEN) for IDH1-Mutated Acute Myeloid Leukemia (AML)

Accrual: 0/5

CRC: TBD

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Molecularly-Driven

2nd+ Line

2nd Line Only

Non-Intensive

UCI 25-105 (NEW)

Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of L-Annamycin for Injection in Combination with Cytarabine Injection vs Placebo in Combination with Cytarabine Injection as Second Line Therapy for Remission Induction in Adults with Refractory/Relapse AML

Accrual: 0/5

CRC: TBD

UCI 25-193

ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 1/10

CRC: Georgina Diaz

Relapsed/Refractory

Molecularly-Driven

UCI 23-44

Venetoclax/Azacitidine v.s
Venetoclax+ KO-530 v.s
cytarabine/daunorubicin
(7+3)+ KO-539 in AML

Accrual: 10/10

CRC: Georgina A.

KMT2A-r/NPM1-m

UCI 23-154

Ziftomenib combinations for
the KMT2A-
rearranged/NPM1 mutant
R/R AML

Accrual: 3/5

CRC: Georgina A.

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Maintenance

High-Risk, HSCT

Salvage Therapy

Newly Diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Ph+ only

Age ≥ 60 years or <60 if non-intensive
CD19+ (≥ 20% lymphoblasts)

SWOG-21CTP-LEUK01

Phase II Trial of Asciminib,
Dasatinib, Prednisone, and
Blinatumomab for Participants with
Newly Dx Ph+ B-ALL

Accrual: 1/5
CRC: Makena Belle Castillo

Age ≥ 75 years or >18 if non-intensive
CD22+ (≥ 20% lymphoblasts)

A041703: Cohort 3

Inotuzumab Ozogamicin Followed
by Blinatumomab for Ph-Negative,
CD22-Positive B-Lineage ALL in
Newly Diagnosed Older Adults or
Adults with R/R Disease

Accrual: 2/5
CRC: Makena Belle Castillo

Ph- only

Age ≥ 18 years & < 40 years
CD22+ (≥ 20% lymphoblasts)

A041501

Addition of Inotuzumab
Ozogamicin to frontline
therapy in young adults (18-
39y/o)

Accrual: 10/15
CRC: Makena Belle Castillo

Age ≥ 18 years

UCI 25-104 (On Hold)

subcutaneous blinatumomab
vs. intravenous
blinatumomab in newly
diagnosed adults with (Ph)- B
cell precursor ALL

Accrual: 0/5
CRC: TBD

Age ≥ 60 years
CD22+ (≥ 20% lymphoblasts)

A041703: Cohort 1

Inotuzumab Ozogamicin
Followed by Blinatumomab for
Ph-Negative, CD22-Positive B-
Lineage ALL in Newly Diagnosed
Older Adults or Adults with R/R
Disease

Accrual: 2/5
CRC: Makena Belle Castillo

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Ph+ only

Ph- only

Age ≥ 12 years
CD19+

Age ≥ 18 years
CD22+

Age ≥ 18 years
CD22+ (≥ 20% lymphoblasts)

26-53 (Hold)

A PhII/III Randomized, Open-Label, Comparison Study of MK-1045 vs Blinatumomab in patients with R/R CD19+ B-ALL

Accrual: 0/5

CRC: TBD

UCI 25-209 (NEW)

UCART22 (allogeneic Anti-CD22 CAR-T) in R/R CD22+ B-ALL

Accrual: 0/3

CRC: TBD

A041703: Cohort 2

Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage ALL in Newly Diagnosed Older Adults or Adults with R/R Disease

Accrual: 2/5

CRC: Makena Belle Castillo

Newly diagnosed

UCI 25-166 (NEW)

Phase 3 Study Evaluating the
Efficacy and Safety of QTX-2101
in Newly Diagnosed Acute
Promyelocytic Leukemia

Accrual: 0/5
CRC: TBD

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Newly diagnosed

UCI 23-189

Frontline Ruxolitinib with De-Intensified HLH-94 for Adults with Hemophagocytic Lymphohistiocytosis (HLH)

Accrual: 2/6

CRC: Alice Ting

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

2nd+ Line

UCI 23-167

Phase I- TERN-701 in patients
w/CML

Accrual: 2/5

CRC: Kelsey E.

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Front Line

Relapsed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended



Newly Diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

SWOG-S2213

Phase III, Randomized Study of
Daratumumab,
Cyclophosphamide, Bortezomib
and Dexamethasone (Dara-VCD)
Induction Followed by Autologous
Stem Cell Transplant or Dara-VCD
Consolidation and Daratumumab
Maintenance in Patients with
Newly Diagnosed AL Amyloidosis

Accrual: 1/5
CRC: Alice T. Ting

UCI 26-116 (NEW)

A Randomized Phase 3 Study to
evaluate the efficacy and safety
of NXC-201 compared with
Daratumumab with
Cyclophosphamide, Bortezomib
and Dexamethasone (CyBorD) in
Newly Diagnosed Systemic AL
Amyloidosis [NEXICART-3]

Accrual: 0/3
CRC: Cristian Franco

Newly Diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Anti-BCMA

UCI 23-158

Phase I/II Study of
 Linvoseltamab (Anti-BCMA X
 Anti-CD3 Bispecific Antibody) in
 Previously Untreated Patients
 with Symptomatic Multiple
 Myeloma
 Accrual: 2/6
 CRC: Alice T. Ting

BsAbs

UCI 26-69 (NEW)

Sequential integration of
 bispecific monoclonal
 antibodies into Treatment of
 Newly Diagnosed Multiple
 Myeloma
 Accrual: TBD
 CRC: TBD

CAR-T

UCI 25-220 (NEW)

A Phase III Randomised Study
 of Consolidation with a Single
 Administration of AZD0120
 Compared with Continuous
 Standard Therapy in
 Participants with NDMM Who
 Are Not Planned to Receive
 ASCT as Initial Therapy
 Accrual: 0/5
 CRC: Cristian Franco

UCI 25-221 (NEW)

A Phase III, Multicentre Study
 to Evaluate Consolidation
 Treatment with AZD0120 vs
 ASCT, in Participants with
 Newly Diagnosed Multiple
 Myeloma who are Transplant
 Eligible
 Accrual: TBD
 CRC: Cristian Franco

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

≥ 1-3 prior lines

UCI 26-07

Phase 3 Randomized Study Comparing JNJ-79635322 vs. Teclistamab in Participants with R/R MM who Have Received 1-3 Prior Lines of Therapy

Accrual: 0/5
CRC: TBD

≥ 2 prior lines

UCI 26-52

A Phase IB, Multi-center, study of talquetamab in combination with iderdomide and Dexamethasone for the treatment of Relapsed or Refractory Multiple Myeloma

Accrual: 0/5
CRC: TBD

≥ 3 prior lines

UCI 25-116

A Phase I Antitumor Activity of SIM0500, A Humanized GPTC5D-BCMA-CD3 Trispecific Antibody, in Participants with R/R MM

Accrual: 0/3
CRC: Alice T. Ting

Maintenance

**ALLIANCE-A062102
(Suspended)**

Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in R/R MM

Accrual: 0/5
CRC: Cristian Franco

CAR-T

UCI 26-33

Expanded Access Program for Mezigdomide (in combination with Carfilzomib/dex or Bortezomib/dex) For Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Accrual: 1/7
CRC: Alice T. Ting

UCI 26-153

A Phase III, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination with Pomalidomide Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma

(2L+ RRMM)
ccrual: 1/7
CRC: Alice T. Ting

Other

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Supportive Care

UCI 24-170

Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Pts With MM Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy

Accrual: 0/10

CRC: Alice T. Ting

UCI 26-51 (NEW)

A Phase 3, Prospective, single-arm study to investigate the efficacy, safety and pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic

Accrual: TBD

CRC: TBD

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 23-19

PhIII Odronextamab Comb
w/CHOP vs Rituximab Comb
w/CHOP

Accrual: 0/5
CRC: Melisa D.

UCI 24-22

Loncastuximab Tesirine and
Rituximab (Lonca-R)
Followed by DA-EPOCH-R in
Previously Untreated High-
risk Diffuse Large B-cell
Lymphoma
Accrual: 0/1

CRC: Melisa D.

26-59 (New)

A Phase III study to
Evaluate The Efficacy of
Surovatamig Combined
with Rituximab,
Cyclophosphamide,
Doxorubicin, Vincristine,
and Prednisone (R-Chop) in
previously untreated Large
B-Cell Lymphoma

Accrual: 0/3
CRC: TBD

ETCTN-10717

Phase Ib/II Trial of
Pidnarulex in MYC Aberrant
Lymphoma

Accrual: 0/2
CRC: Melisa D.

Relapsed/Refractory

Tertiary Relapsed/Refractory

S2114

Consolidation therapy
following CD19 CAR T-cell tx

Accrual: 1/6

CRC: Phoebe Lee

2+ Lines

UCI 23-114

Safety and Efficacy of IMPT-
314, a CD19/20 Bispecific
Chimeric Antigen Receptor
(CAR) T Cell Therapy in B-cell
NHL

Accrual: 9/15

CRC: Phoebe Lee

ETCTN-10717

Phase Ib/II Trial of
Pidnarulex in MYC Aberrant
Lymphoma

Accrual: 0/2

CRC: Melisa D.

26-64 (New)

A randomized study
Cemacabtagene
Ansegedleucel in Participants
with Minimal Residual Disease
After Response to First Line
therapy for Large B-Cell
Lymphoma (Alpha3)

Accrual: 0/3

CRC: TBD

Open to Accrual

Low Accruing

Pending Activation/Suspended

Molecularly-Driven

Newly diagnosed

Low Grade

SWOG S2308

Phase III Study of
Mosunetuzumab vs.
Rituximab for Low Tumor
Burden Follicular
Lymphoma

Accrual: 2/5

CRC: Melisa D.

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

2nd Line+

UCI 22-134

Oral AS-1763 in patients
w/ previously treated
CLL/SLL or NHL

Accrual: 5/9

CRC: Kelsey E.

3rd Line+

Consolidation

S2114

Consolidation therapy
following CD19 CAR T-
cell tx

Accrual: 1/6

CRC: Phoebe Lee

Maintenance

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Cell Therapy

TF FL or FL Grade 3B

On-label & Nonconforming

UCI 23-114

Safety and Efficacy of
IMPT-314, a CD19/20
Bispecific Chimeric
Antigen Receptor (CAR) T
Cell Therapy in B-cell NHL
Accrual: 10/15
CRC: Phoebe Lee

UCI 25-70

Ph III of LYL314 in 2L for
R/R B-Cell NHL
Accrual: 0/7
CRC: Cristian F.

UCI 25-63

EAP for Lisocabtagene
Maraleucel (liso-cel) that is
Nonconforming for
Commercial Release
Accrual: 0/5
CRC: Cristian Franco

Relapsed/Refractory

3rd+ LineUCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or
NHL

Accrual: 5/9

CRC: Kelsey E.

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Cell Therapy

Molecularly-Driven

3rd Line+



Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

EBV+

Molecularly-Driven

3rd Line+

Newly diagnosed

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

High-Risk

S1925

Venetoclax+Obnutumab
early intervention vs.
delayed therapy in
asymptomatic high-risk
CLL/SLL

Accrual: 5/10

CRC: Kelsey E.

Front Line

UCI 25-192 (NEW)

Randomized Study of
Sonrotoclax (BGB-11417)
Plus Zanubrutinib (BGB-
3111) Compared with
Venetoclax Plus
Acalabrutinib in Patient
with Previously Untreated
CLL

Accrual: 0/7

CRC: TBD

S2504

A Randomized Phase III
Study of Pirtobrutinib Plus
R-CHOP vs. R-CHOP for
Participants with Previously
Untreated Richter
Transformation (pirAMID)

Accrual: 0/5

CRC: Kelsey E.

Follow Up

UCI 25-205 (NEW)

Long-term follow-up of
ibrutinib plus venetoclax in
patients with treatment-
naïve CLL/SLL

Accrual: 0/6

CRC: TBD

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

2nd+ LineUCI 24-190

A Phase III Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax + Rituximab in Patients With R/R CLL/SLL

Accrual: 1/7

CRC: Kelsey E. McAbee

UCI 24-32

Epcoritamab as Consolidation Therapy for High-risk Patients with Chronic Lymphocytic Leukemia on Bruton Tyrosine Kinase Inhibitor

Accrual: 0/24

CRC: Kelsey E.

UCI 26-65 (NEW)

Study of Surovatamig as Consolidation Therapy vs Observation after First-line Induction Therapy in Participants with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with Unmutated IGHV (SOUNDTRACK-C1)

Accrual: TBD

CRC: TBD

3rd+ LineUCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

CRC: Kelsey E.

UCI 26-36 (NEW)

Phase 2 Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) (CLL) or (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Accrual: 0/5

CRC: TBD

UCI 26-84 (Abandoned)

Phase 2 study of MK-1045 in Participants with Hematologic Malignancies

Accrual: TBD

CRC: TBD

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

2+ Lines

Consolidation

S2114

Consolidation therapy following
CD19 CAR T-cell tx

Accrual: 1/6

CRC: Phoebe Lee

26-64 (NEW)

A randomized study of
Cemacabtagene Ansegedleucel
in Participants with Minimal
Residual Disease After
Response to First Line therapy
for Large B-Cell Lymphoma
(Alpha3)

Accrual: 0/3

CRC: TBD

Relapsed/Refractory

Open to Accrual

Low Accruing

Pending Activation/Suspended

2+ Lines

Molecularly-Driven

Cell Therapy

UCI 23-114

Safety and Efficacy of IMPT-314,
a CD19/20 Bispecific Chimeric
Antigen Receptor (CAR) T Cell
Therapy in B-cell NHL

Accrual: 10/15

CRC: Phoebe Lee

3rd line+

UCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or
NHL

Accrual: 5/9

CRC: Kelsey E.

ETCTN-10717

Phase Ib/II Trial of Pidnarulex in
MYC Aberrant Lymphoma

Accrual: 0/2

CRC: Melisa D.

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

1st Line+

UCI 21-99

ONO-4685 given as
monotherapy

Accrual: 5/10

CRC: Melisa D.

UCI 25-74 (Reopened)

A Phase I/II Study to Evaluate
the Safety and Efficacy of DR-
01 in Subjects with LGLL or
Cytotoxic Lymphomas

Accrual: 4/5

CRC: Melisa D.

UCI 25-142

Study of KK2223 in
Participants with Relapsed or
Refractory T-cell Non-Hodgkin
Lymphoma

Accrual: 0/5

CRC: TBD

Newly Diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Treatment-Naive

Post-Induction Treatment

2nd Line +**UCI 22-18**

Investigation of MRD in patients with treatment-naïve systemic T cell lymphoma tx w/ a brentuximab-containing regimen

Accrual: 1/6

CRC: TBD

ECOG EA4232

Phase III Study to Evaluate ASCT in Patients with PTCL that Achieved a First CR1 Following Induction Therapy (PTCL-STAT)

Accrual: 0/5

CRC: TBD

UCI 25-74 (Reopened)

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 4/5

CRC: Melisa D.

UCI 24-174

ITK Inhibitor Soquelitinib vs. MD Choice SOC Tx in Participants w/ R/R PTCL NOS, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 1/5

CRC: Melisa D.

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

R/R

1st Line +2nd Line +3rd Line +UCI 24-174

ITK Inhibitor Soquelitinib vs.
MD Choice SOC Tx in
Participants w/ R/R PTCL
NOS, Follicular Helper T-cell
Lymphomas, or Systemic
Anaplastic Large-cell
Lymphoma

Accrual: 1/5

CRC: Melisa D.

UCI 21-99

ONO-4685 given as
monotherapy

Accrual: 5/10

CRC: Melisa D.

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

R/R

1st Line +2nd Line +3rd Line +**UCI 25-74**

Phase I/II Study to Evaluate
the Safety & Efficacy of DR-
01 in Subjects with LGLL or
Cytotoxic Lymphomas

Accrual: 4/5

CRC: Melisa D.

UCI 25-142

Study of KK2223 in
Participants with Relapsed or
Refractory T-cell Non-
Hodgkin Lymphoma

Accrual: 0/5

CRC: TBD

Newly Diagnosed

COG-AHOD2131

Standard Therapy with
Immuno-oncology Therapy
for Newly Diagnosed Stage I
and II Classical Hodgkin
Lymphoma

Accrual: 2/5

CRC: Melisa D.

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

2nd Line Only**UCI 25-21 (NEW)**

Pembrolizumab and GVD
with ctDNA-guided
Consolidation in Patients
with Relapsed or Refractory
Classic Hodgkin Lymphoma

Accrual: 0/5

CRC: TBD

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

Basket study

Supportive Care

Open to Accrual
 Low Accruing
 Pending Activation/Suspended

Autologous

UCI 23-193

CTO1681 for the Prevention & Treatment of CRS in pts w/ DLBCL receiving CAR-T Therapy

Accrual: 1/5

CRC: Cristian F. (MM),
Phoebe Lee (NHL)

Alliance-A062102 (Suspended)

Iberdomide Maintenance Therapy Following Ide-Cel CAR-T in R/R Multiple Myeloma

Accrual: 0/5

CRC: Cristian F.

S2114

Consolidation Therapy Following CD19 CAR-T for R/R Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Accrual: 1/6

CRC: Phoebe Lee

26-64 (New)

A randomized study Evaluating the Efficacy and Safety of Cemacabtagene Ansedgleucel in Participants with Minimal Residual Disease After Response to First Line therapy for Large B-Cell Lymphoma (Alpha3)

Accrual: 0/3

CRC: TBD

Allogeneic

UCI 21-90

Risk-ADAPTEd conditioning regimen for AHSCT

Accrual: 37/48

CRC: Mario D.

UCI 22-188

Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHSCT

Accrual: 25/50

CRC: Mario D.

UCI 24-131 (Suspended)

Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Accrual: 0/5

CRC: Cristian F.

UCI 25-139 (HOLD)

Efficacy of SER-155 to Reduce Bloodstream Infections in Adults Undergoing Allogeneic HCT

Accrual: 0/5

CRC: TBD

LTFU / Other

Autologous

UCI 21-184

Long-term safety of CAR-T inpatient w/ heme malignancies

Accrual: 7/7

CRC: Cristian Franco

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Allogeneic

UCI 24-110

HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical HSCT

Accrual: 3/7

CRC: Mario D.

UCI 26-86 (NEW)

Prospective observational cohort study in US transplant centers

Accrual: 0/30

CRC: Mario Diaz



Other

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 14-89

Hematologic Malignancies
Biorepository for human
research

Accrual: 322/500
CRC: Helen Huang

UCI 24-05

Repurposing Riluzole for
Augmenting Brain-Derived
Neurotrophic Factor (BDNF) Levels
and Cognitive Function in Patients
Experiencing Cancer-Related
Cognitive Impairment: An
Interventional Pilot Clinical
Trial

Accrual: 30/59
CRC: TBD

UCI 26-51 (NEW)

A Phase 3 Single-arm study to
investigate IgPro20 in Subjects
with Secondary Immune
Deficiency due to Hematologic
Malignancies Treated with B-cell
Depleting Therapies

Accrual: TBD
CRC: TBD

UCI 22-194

A Retrospective analysis of L-
carnitine for Treatment and/or
Prevention of L-Asparaginase
Hepatotoxicity during Induction
or Salvage Chemotherapy for
Hematologic Malignancies

Accrual: TBD
CRC: TBD

UCI 25-198 (NEW)

A multicenter protocol for
haploidentical stem cell
transplantation: Optimization of
transplant outcomes in a
collaborative consortium

Accrual: TBD
CRC: TBD

UCI 25-195

Clinical utility Karius testing
for diagnosis & management
of suspected infections in
adult immunocompromised
patients

Accrual: 0/10
CRC: TBD

UCI 25-48

Riluzole FOR Preventing
Cognitive Dysfunction in
Cancer Patients Receiving
Chemotherapy (REFOCUS)

Trial Accrual: 12/20
CRC: TBD



Other

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 25-226 (NEW)

Prospective Observational
International Registry of
Patients with Newly
Diagnosed Burkitt
Lymphoma
Accrual: 0/5
CRC: TBD

UCI 26-101 (NEW)

ASC4REAL-2: A real-world
chronic myelogenous
leukemia (CML) patient
disease registry to describe
patient experience and clinical
outcomes among patients
with CML receiving approved
first- or second-line tyrosine
kinase inhibitor (TKI) therapy

Accrual: 0/11
CRC: TBD